ADGM vs BEAT vs CRMD vs ATRC vs ABLV

For growth investors, CorMedix Inc.

(CRMD) is the stronger pick with 617. 0% revenue growth year-over-year, versus -13. 5% for Able View Inc. (ABLV). CorMedix Inc. (CRMD) offers the better valuation at 3. 9x trailing P/E (14. 2x forward), making it the more compelling value choice. Analysts rate CorMedix Inc. (CRMD) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, CorMedix Inc.

is actually cheaper at 14. 2x.

Over the past 5 years, CorMedix Inc.

(CRMD) delivered a total return of -6. 9%, compared to -89. 5% for Adagio Medical Holdings, Inc. (ADGM). Over 10 years, the gap is even starker: ATRC returned +84. 4% versus ADGM's -89. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Able View Inc.

(ABLV) is the lower-risk stock at -0. 43β versus CorMedix Inc. 's 1. 42β — meaning CRMD is approximately -430% more volatile than ABLV relative to the S&P 500. On balance sheet safety, AtriCure, Inc. (ATRC) carries a lower debt/equity ratio of 18% versus 157% for Able View Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), CorMedix Inc.

(CRMD) is pulling ahead at 617. 0% versus -13. 5% for Able View Inc. (ABLV). On earnings-per-share growth, the picture is similar: CorMedix Inc. grew EPS 780. 0% year-over-year, compared to -175. 0% for Able View Inc.. Over a 3-year CAGR, CRMD leads at 1583% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

CorMedix Inc.

(CRMD) is the more profitable company, earning 52. 3% net margin versus -199. 9% for Adagio Medical Holdings, Inc. — meaning it keeps 52. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CRMD leads at 48. 2% versus -232. 3% for ADGM. At the gross margin level — before operating expenses — CRMD leads at 88. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, CorMedix Inc.

(CRMD) trades at 14. 2x forward P/E versus 428. 7x for AtriCure, Inc. — 414. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ATRC: 84. 6% to $51. 33.

In this comparison, ABLV (0.

2% yield) pays a dividend. ADGM, BEAT, CRMD, ATRC do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Able View Inc.

(ABLV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 43)). Both have compounded well over 10 years (ABLV: -85. 3%, CRMD: -51. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ADGM (Healthcare) and BEAT (Healthcare) and CRMD (Healthcare) and ATRC (Healthcare) and ABLV (Communication Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ADGM is a small-cap quality compounder stock; BEAT is a small-cap quality compounder stock; CRMD is a small-cap high-growth stock; ATRC is a small-cap quality compounder stock; ABLV is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.